Creatine Energizes Dendritic Cells to Strengthen Cancer Immunity, UCLA Study Shows

Table of Contents

1. Key Highlights
2. Introduction
3. Why dendritic cells matter for cancer immunotherapy
4. How creatine supplies immune cells with energy
5. Experimental evidence: what the UCLA team did and found
6. How creatine could augment current immunotherapies
7. Where creatine fits in the broader landscape of metabolic immunology
8. Potential benefits and measurable outcomes for patients
9. Safety, dosing, and what is known about creatine in humans
10. Questions and caveats researchers must address
11. Potential trial designs and translational pathways
12. Balancing optimism with scientific rigor
13. Real-world analogies and precedents
14. Practical considerations for clinicians and patients
15. Limitations inherent in preclinical models
16. The ethical and regulatory path forward
17. Next steps indicated by the UCLA team
18. Broader implications for cancer care and research
19. Practical takeaways for researchers and industry
20. Closing reflection
21. FAQ

Key Highlights

• UCLA researchers found creatine supports dendritic cell activation and survival, increasing ATP production and enhancing the immune system’s ability to prime killer T cells against tumors in mice and human cells.
• Creatine supplementation slowed tumor growth in mouse models and improved the function of dendritic cells used to stimulate T cells in vitro, suggesting potential to boost immunotherapy and dendritic cell–based vaccines.

Introduction

Immunotherapy has transformed cancer care by directing patients’ own immune systems to attack tumors. Despite dramatic successes for some people, most patients do not benefit from current approaches that primarily target T cells. Researchers at UCLA now report a new angle: creatine, the same supplement widely used by athletes, can invigorate dendritic cells—the immune system’s scouts and commanders—helping them activate and guide cancer-killing T cells. Experiments in mice and human cells show creatine increases energy stores inside dendritic cells, improves their survival and activation, and amplifies the downstream T cell response. These findings reposition creatine from a performance supplement to a metabolic ally in anti-cancer immunity and point toward new strategies for combining metabolic support with established immunotherapies.

Why dendritic cells matter for cancer immunotherapy

Dendritic cells (DCs) are specialized antigen-presenting cells that detect tumor-derived material, process it, and display fragments to T cells. That presentation, together with co-stimulatory signals and inflammatory cues, determines whether T cells become effective cancer killers. Most FDA-approved immunotherapies—checkpoint inhibitors, adoptive T cell therapies, and many experimental vaccines—depend on a functional antigen presentation step. When dendritic cells are absent, suppressed, or metabolically exhausted inside tumors, T cells receive weak or chaotic activation and fail to mount a durable attack.

Cancer and its microenvironment place severe metabolic constraints on immune cells. Tumors voraciously consume glucose and other nutrients and create hypoxic, acidic spaces that impede immune function. Immune cells that infiltrate these environments must operate with limited resources. Boosting dendritic cell metabolism therefore represents a strategic lever: rather than only amplifying T cells at the end of the process, strengthening the cells that initiate and organize the response can improve the quality and sustainability of anti-tumor immunity.

How creatine supplies immune cells with energy

Creatine is a well-characterized molecule in muscle and brain physiology. Cells use creatine to form phosphocreatine, a high-energy reservoir that rapidly regenerates ATP—cells’ universal energy currency—through the creatine kinase reaction. This phosphate shuttle stabilizes cellular ATP supply during spikes in demand and under fluctuating nutrient conditions.

The UCLA team found dendritic cells that infiltrate tumors express higher levels of the gene encoding the creatine transporter, enabling increased uptake of extracellular creatine. Once inside, creatine participates in the phosphocreatine system, raising intracellular ATP and maintaining inflammatory signaling required for full dendritic cell activation. Conceptually, creatine behaves like a rechargeable battery for immune cells in nutrient-scarce environments, allowing them to sustain antigen processing, co-stimulatory molecule expression, and cytokine secretion when competing against rapidly growing tumor cells.

These biochemical insights link two previously separate threads in oncology: metabolic support for immune cells and targeted immunotherapies. The practical consequence is straightforward—if dendritic cells can be armed metabolically, they can present antigen more effectively and instruct T cells to attack.

Experimental evidence: what the UCLA team did and found

The research combined gene expression analysis, genetic engineering, in vitro functional assays, and mouse tumor models to explore how creatine affects dendritic cells and the downstream anti-tumor immune response.

• Gene expression profiling showed that dendritic cells inside mouse tumors upregulated the creatine transporter gene compared with dendritic cells in healthy tissue. That pattern suggests tumor-infiltrating DCs attempt to scavenge creatine from their surroundings.
• To test whether creatine uptake mattered, researchers engineered dendritic cells lacking the creatine transporter. These deficient DCs exhibited poorer survival, lower markers of activation, and reduced capacity to prime T cells. When cultured with T cells, the outcome was clear: fewer T cell divisions and lower production of signaling molecules necessary for effective tumor killing.
• The team supplemented tumor-bearing mice with daily creatine injections. Treated mice showed slower melanoma growth. Tumors from these mice contained more dendritic cells, and those DCs displayed higher functional activity, producing greater amounts of chemoattractant signals that recruit additional immune cells.
• Metabolomic analyses revealed increased ATP levels inside dendritic cells after creatine supplementation. The higher ATP supported the inflammatory signaling cascades needed for DC activation.
• Translational experiments used human monocyte-derived dendritic cells, commonly employed in experimental dendritic cell vaccines. Creatine exposure improved their activation profile and their ability to stimulate human T cells against a cancer-associated target. That suggests creatine could be used both as a systemic supplement and as a component of ex vivo DC vaccine manufacturing.

These results together show creatine directly supports dendritic cell energetics and function, improving the immune system’s capacity to detect and direct attacks against tumors.

How creatine could augment current immunotherapies

Current immunotherapies have made clear that re-energizing the immune system produces clinical benefit. Checkpoint inhibitors—antibodies targeting PD-1, PD-L1, or CTLA-4—release brakes on T cells, enabling attacks that previously failed. CAR-T and engineered T cell therapies supply new receptors that target tumor antigens. Yet these strategies rely on successful antigen recognition and T cell priming steps. If dendritic cells fail to present antigen properly or provide the correct signals, unleashing T cells produces limited returns.

Creatine offers at least two strategic applications to amplify existing therapies:

1. Adjunctive supplementation to systemic immunotherapy. Patients receiving checkpoint inhibitors could take creatine to fortify dendritic cells within tumors. That could increase the pool of effective antigen presentation, making T cells released by checkpoint blockade more likely to encounter properly primed antigens and co-stimulation. Enhanced DC activity might also promote broader T cell repertoires, reducing the chance of immune escape.
2. Enhancing dendritic cell–based vaccines. Several experimental therapies use ex vivo–generated dendritic cells loaded with tumor antigens and then administered to patients. The UCLA team demonstrated that creatine treatment improves activation of human monocyte-derived DCs and their ability to stimulate T cells. Adding creatine into DC production protocols could yield vaccines with higher potency before injection.

Those applications dovetail with the observation that only a minority of patients derive durable benefit from current immunotherapies. Strengthening antigen presentation early in the immune cascade addresses a key bottleneck in the response pathway.

Where creatine fits in the broader landscape of metabolic immunology

Immunometabolism—how metabolic processes shape immune cell function—has emerged as a central theme in cancer biology. Strategies that inhibit tumor metabolism can starve cancer cells, while approaches that bolster immune cell metabolism help immune cells compete in hostile microenvironments. Examples include altering glycolysis, fatty acid oxidation, or amino acid availability to favor immune activation.

Creatine occupies a distinct niche within this landscape. It does not primarily alter global nutrient pathways such as glucose metabolism; instead, it provides a rapid, portable mechanism for ATP regeneration. That makes it particularly useful where intermittent spikes in energy demand occur—antigen processing, migration toward lymph nodes, or sustained cytokine secretion during T cell priming.

Real-world parallels exist: endurance athletes use creatine to maintain muscle performance during repeated exertion; analogously, dendritic cells must sustain bursts of activity during antigen uptake and presentation. The UCLA findings show immune cells exploit the same chemical principle. Creatine therefore expands the toolbox for metabolic modulation of the immune system by offering a direct route to ATP replenishment rather than broad reprogramming of foundational metabolic pathways.

Potential benefits and measurable outcomes for patients

If creatine supplementation proves effective in clinical trials, its benefits could manifest across several measurable outcomes:

• Increased response rates to checkpoint inhibitors. By raising the number and activity of dendritic cells capable of priming T cells, more patients may respond to therapies that rely on effective T cell activation.
• Enhanced efficacy of dendritic cell vaccines. Ex vivo treatment of DCs with creatine could yield vaccines that trigger stronger T cell responses, potentially converting marginal clinical signals into meaningful tumor control.
• Expanded durability of immune responses. Improved antigen presentation can promote formation of memory T cells, which provide long-term surveillance against tumor recurrence.
• Better infiltration of immune cells into tumors. Creatine-treated DCs produced more chemokines that attract immune cells; a more inflamed microenvironment correlates with better responses to many immunotherapies.

Each of these potential outcomes would require carefully designed clinical trials and validated biomarkers—changes in tumor-infiltrating lymphocyte profiles, cytokine signatures, and imaging-based measures of tumor burden are among the plausible endpoints.

Safety, dosing, and what is known about creatine in humans

Creatine monohydrate is one of the most extensively studied dietary supplements. Among healthy adults, typical dosing includes an initial loading phase (often 20 grams per day divided over several doses for 5–7 days) followed by a maintenance dose of roughly 3–5 grams per day. Many athletes and recreational users take creatine for months to years without serious adverse events. Reported side effects are usually mild and include short-term weight gain due to water retention, gastrointestinal upset when doses are excessive, and rare reports of cramping.

Clinical recommendations about creatine must be conservative for patients with cancer. The UCLA investigators emphasize that their findings stem from cell-based assays and animal models; they do not constitute clinical guidance. Patients receiving cancer therapy should not begin any supplement without consulting their oncologist. Potential interactions between creatine and specific cancer treatments—chemotherapy agents, immunosuppressants, or targeted therapies—remain largely uncharacterized.

People with preexisting renal impairment represent another group requiring caution. Although creatine has not been definitively shown to cause kidney damage in healthy individuals, creatine metabolism influences creatinine measures that clinicians use to track renal function. Monitoring and physician oversight are prudent when introducing creatine to patients whose renal reserve may already be compromised.

Questions and caveats researchers must address

The UCLA study opens several lines of inquiry that will determine whether creatine will translate into safe, effective clinical tools.

• Will systemic creatine supplementation selectively help dendritic cells without feeding tumor cells? Tumor cells can express creatine transporters too. Determining cell-type–specific uptake patterns and transporter expression in different tumor types will be critical. Some cancers may be able to use creatine to their advantage; others may not. Preclinical work should map transporter expression across tumor types and states.
• What dose, schedule, and route best support dendritic cells in patients? The mice in the study received daily injections. Whether oral supplementation in humans achieves comparable intratumoral levels, and whether loading doses or steady-state maintenance are preferable, requires pharmacokinetic and pharmacodynamic studies.
• Could creatine alter immune tolerance or autoimmune risk? Enhancing dendritic cell activation carries theoretical risks of promoting off-target immune responses. Early-phase trials will need to monitor for autoimmune phenomena and aberrant inflammation.
• How does creatine interact with different classes of cancer therapy? Combining creatine with checkpoint inhibitors, adoptive cell therapies, or radiation may yield synergistic effects—or unexpected antagonism. Preclinical combination studies followed by carefully staged clinical trials are necessary.
• Are there biomarkers that predict which patients will benefit? Measuring creatine transporter expression in tumor-infiltrating DCs, or systemic indicators of creatine uptake and phosphocreatine levels, could enable patient selection and dose optimization. Stratified trials may reveal subgroups that derive disproportionate benefit.

Addressing these questions requires coordinated laboratory and clinical programs. The UCLA team has signaled intent to work with clinicians on trials, but rigorous safety and efficacy data must precede any routine recommendation.

Potential trial designs and translational pathways

Translating the preclinical findings into clinical practice could follow several paths, each with distinct design considerations.

• Phase 1 safety trial of oral creatine supplementation in patients receiving checkpoint inhibitors. Objectives would include safety, tolerability, and pharmacokinetics, plus exploratory immune endpoints (tumor-infiltrating DC numbers, T cell activation markers). Dose-escalation cohorts could identify tolerable regimens and indicate whether oral dosing reaches biologically active levels in tumor tissue.
• Ex vivo dendritic cell vaccine optimization. Trials could compare standard DC vaccines with DCs produced in creatine-supplemented culture. Primary endpoints would be immunogenicity measures—breadth and magnitude of vaccine-induced T cell responses—and secondary endpoints could include safety and preliminary signals of anti-tumor effect.
• Combination trials with adoptive cell therapies. Since adoptive T cell transfers depend on antigen presentation for homologous epitope expansion and sustained responses, pairing creatine-augmented DC vaccines or systemic supplementation with CAR-T therapies may improve persistence and efficacy. Early trials would prioritize safety and immune monitoring.
• Biomarker-driven trials. Selecting patients whose tumors show high DC creatine transporter expression could enrich for responders. Such precision approaches would require validated assays for transporter expression in biopsy specimens or noninvasive surrogates.

Trial designs should incorporate serial tissue sampling when feasible, allowing comparison of intratumoral immune composition before and after creatine exposure. Imaging biomarkers and circulating tumor DNA (ctDNA) could provide additional, less invasive measures of clinical activity.

Balancing optimism with scientific rigor

The line between promising laboratory results and patient benefit has been drawn many times in oncology. Numerous agents that showed compelling preclinical activity stalled in clinical testing. Creatine’s advantages—low cost, broad availability, and a long safety record in healthy populations—help make it an attractive candidate. Still, the stakes are different when considering people with active malignancy.

Scientific rigor demands randomized, controlled trials with appropriate safety monitoring. Mechanistic studies should explore tumor-specific effects and potential adverse outcomes. Regulators will require careful demonstration that any supplementation or manufacturing change for cell-based vaccines does not compromise treatment safety.

The UCLA findings provide a clear mechanistic rationale and initial proof-of-concept. They also supply concrete experimental strategies for translation: assay transporter expression in human tumors, test pharmacokinetics in humans with cancer, and design early-phase trials combining creatine with standard immunotherapies.

Real-world analogies and precedents

Several precedents illustrate how metabolic modulation can influence cancer therapy:

• Sipuleucel-T (Provenge) offers a historical example of a cell-based immunotherapy that uses autologous antigen-presenting cells to stimulate immune responses in prostate cancer. Its approval established that manipulating antigen-presenting cells can produce measurable clinical benefit. Creatine-enhanced dendritic cell vaccines could be seen as an evolution of this concept—optimizing the metabolic state of antigen-presenting cells to improve potency.
• Trials of metabolic inhibitors—targeting glycolysis or glutamine pathways in tumors—demonstrate how shifting metabolic landscapes can alter immune responses. Creatine introduces the opposite strategy: supplying an energy buffer to immune cells rather than directly inhibiting tumor metabolism.
• Nutritional and metabolic interventions in oncology, such as ketogenic diets or amino acid deprivation strategies, illustrate the complexity of systemic metabolic manipulation. Creatine’s localized mode of action—directly replenishing ATP via the phosphocreatine system—may avoid some systemic trade-offs, but the potential for unintended tumor support remains an active concern.

These precedents underscore the need for targeted, hypothesis-driven clinical programs.

Practical considerations for clinicians and patients

Until clinical trials define safety and efficacy, clinicians should approach creatine supplementation for cancer patients cautiously.

• Discuss any planned supplementation with the oncology care team. A physician can assess renal function, current therapy regimens, and potential interactions.
• If considering participation in a research study, patients should seek trials that include close monitoring of immune and renal markers and have explicit safety stopping rules.
• Be wary of off-label commercial claims. Preclinical data can generate enthusiasm, but controlled studies are necessary to determine whether creatine improves outcomes and at what cost.

For clinicians designing trials or considering ex vivo use in DC vaccine protocols, immediate priorities include standardizing creatine concentrations for culture, defining quality-control metrics for DC activation, and establishing assays to measure intracellular ATP and phosphocreatine in manufactured cells.

Limitations inherent in preclinical models

Mouse models and in vitro human cell assays are indispensable tools, but they have limitations:

• Mice differ from humans in immune system biology and pharmacokinetics. A dose that yields biologically active intratumoral creatine in mice may not translate to humans.
• Tumor models often use homogeneous tumor cell lines and controlled tumor initiation. Human cancers are genetically and microenvironmentally diverse, and their interactions with immune cells are more complex.
• In vitro assays of dendritic cell activation do not replicate the full tumor microenvironment, including vascular dynamics, stromal interactions, and the microbiome—factors that modulate immunity.

Recognizing these gaps directs next steps: first, thorough pharmacology and toxicology studies; second, pilot human trials with robust tissue-based immune monitoring; third, iterative refinement of dosing and patient selection based on early human data.

The ethical and regulatory path forward

Conducting trials that combine dietary supplements with cancer therapies raises both ethical and regulatory questions. Creatine itself is sold as a dietary supplement in many countries, but when administered as part of a cancer therapy regimen or used in manufacturing of a cellular product, regulatory oversight intensifies. Institutional review boards, clinical trial oversight committees, and, ultimately, regulatory agencies will require clear evidence of safety and standardized manufacturing processes if creatine is introduced into a therapeutic protocol.

Ethical considerations include equitable access: if creatine augmentation proves beneficial, its low cost could facilitate broad adoption, but ensuring consistent quality and supply will matter. Trials must also ensure informed consent processes clearly present the preclinical nature of the evidence and the known and unknown risks.

Next steps indicated by the UCLA team

The investigators have pointed to several practical next moves. They plan to collaborate with clinicians on initial human studies and to explore how creatine might be used both as a supplement for patients and as a component of dendritic cell vaccine production. Specifically, priorities include:

• Confirming the presence and role of the creatine transporter in human tumor-infiltrating dendritic cells across diverse cancer types.
• Conducting pharmacokinetic studies to determine whether oral creatine achieves active concentrations in human tumors and immune cells.
• Designing safety-focused, early-phase clinical trials that pair creatine with established immunotherapies, accompanied by detailed immune monitoring.
• Refining ex vivo DC manufacturing protocols to identify creatine concentrations and exposure schedules that maximize vaccine potency without compromising cell viability or function.

These steps form a translational roadmap that balances scientific caution with the urgency of improving outcomes for patients who currently derive limited benefit from available immunotherapies.

Broader implications for cancer care and research

If subsequent studies confirm and extend these findings, the implications would be significant:

• A simple, inexpensive supplement could become a standard adjunct to immunotherapy, widening access to effective treatment for more patients.
• Cellular therapy manufacturing protocols could adopt metabolic conditioning as a routine step, improving potency of personalized vaccines and other cell-based treatments.
• The study reinforces the importance of metabolic support in immuno-oncology, encouraging additional research into targeted metabolic cofactors that selectively benefit immune cells.
• New biomarkers and companion diagnostics could emerge, enabling clinicians to identify patients most likely to benefit from metabolic supplementation strategies.

These outcomes would reflect a broader shift: treating cancer not only by targeting tumor cells directly but by strategically strengthening the immune cells that perform surveillance and destruction.

Practical takeaways for researchers and industry

Researchers designing follow-up studies should prioritize translational relevance:

• Use patient-derived tumor samples to map creatine transporter expression and metabolic phenotypes.
• Incorporate combinations with clinically used immunotherapies early in preclinical testing to detect synergy or antagonism.
• Standardize assays for intracellular ATP and phosphocreatine in immune cells as pharmacodynamic readouts.
• Engage with biomanufacturing teams to incorporate creatine into cell therapy protocols under Good Manufacturing Practice (GMP) conditions if ex vivo use proves beneficial.

Industry partners developing immunotherapies might evaluate whether metabolic co-treatments like creatine could differentiate their products by improving response durability and broadening indication populations.

Closing reflection

The UCLA study reorients attention toward the immune system’s metabolic needs. By showing that creatine can support dendritic cells—the cells that initiate and shape anti-tumor responses—the research invites a practical reframing of immunotherapy: energy supply matters. Metabolic interventions that restore or enhance the immune system’s energetic capacity have the potential to convert partial responses into durable remissions. Achieving that promise will require rigorous clinical testing, careful attention to safety, and thoughtful integration with existing therapeutic regimens.

FAQ

Q: Does this study prove creatine treats cancer in humans?
A: No. The experiments were conducted in mouse models and human cells in vitro. Those findings are encouraging but not sufficient to establish clinical efficacy. Clinical trials are required to test safety and benefit in people.

Q: Can cancer patients start taking creatine now to improve treatment outcomes?
A: Patients should not begin any supplement without consulting their oncology team. Creatine interacts with physiology in ways that could affect renal monitoring and possibly interact with cancer therapies. Physicians will need evidence from clinical trials to make treatment recommendations.

Q: Is creatine safe for most people?
A: For healthy adults, creatine monohydrate is generally considered safe at commonly used doses (maintenance ~3–5 g/day). Reported side effects are usually mild, including weight gain from water retention and occasional gastrointestinal upset. People with preexisting kidney disease or other significant medical issues should avoid unsupervised supplementation.

Q: How might creatine be used clinically if trials are positive?
A: Two likely paths exist: oral or parenteral supplementation for patients undergoing immunotherapy, and inclusion of creatine in ex vivo culture protocols to enhance dendritic cell vaccines before administration. Each application requires tailored dosing, timing, and safety monitoring.

Q: Could tumors use creatine to grow faster?
A: Tumor cells can sometimes exploit available metabolites. The possibility that creatine could be taken up by tumor cells and support their metabolism is a valid concern. Preclinical and clinical studies must investigate whether creatine preferentially benefits immune cells or whether certain tumors could co-opt it.

Q: What types of cancer could benefit most from creatine-based strategies?
A: That remains unknown. Tumors with poor immune infiltration or tumors whose microenvironments suppress DC function might be promising targets. Mapping creatine transporter expression and DC activity across tumor types will inform patient selection.

Q: Will creatine replace existing immunotherapies?
A: Creatine is unlikely to replace foundational immunotherapies. Its potential role is as an adjunct—strengthening immune cell function to improve response rates and durability when combined with checkpoint inhibitors, adoptive cell therapies, or vaccines.

Q: How soon might clinical trials begin?
A: The UCLA team indicated plans to work with clinicians on trials. The timeline will depend on approvals, funding, and preclinical planning. Early-phase safety and pharmacokinetic studies are typically the first step and may take months to initiate.

Q: Are there biomarkers to identify who will respond to creatine augmentation?
A: Potential biomarkers include creatine transporter levels in tumor-infiltrating dendritic cells, intratumoral ATP or phosphocreatine measures, and immune cell activation signatures. These require validation in clinical studies.

Q: Does creatine affect T cells directly?
A: Prior work by the same research group showed creatine boosts the activity of killer T cells. The current study adds that creatine also supports dendritic cells, indicating a dual role in the immune response.

Q: Could creatine supplementation produce autoimmune side effects?
A: Any intervention that enhances immune activation carries some theoretical risk of off-target immune responses. Early human trials will need to monitor for autoimmune events and inflammatory complications.

Q: Where can I read the original study?
A: The study is published in iScience under the title “Creatine uptake promotes dendritic cell activation and enhances antitumor immunity” (DOI: 10.1016/j.isci.2026.115436).